Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

Faivre‐Finn et al. (Tue,) studied this question.

www.synapsesocial.com/papers/69d74462aa68b335b4f30c81 — DOI: https://doi.org/10.1016/s1470-2045(17)30318-2

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Protocol for the CONVERT trial—Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status· 2016 · 41 citations
2. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis.· 1992 · 815 citations
3. Keynote address on biostatistics and data retrieval.· 1973 · 485 citations
4. A Meta-Analysis of Thoracic Radiotherapy for Small-Cell Lung Cancer· 1992 · 1,330 citations
5. Time Between the First Day of Chemotherapy and the Last Day of Chest Radiation Is the Most Important Predictor of Survival in Limited-Disease Small-Cell Lung Cancer· 2006 · 329 citations